Medwire News reports from the EASD: Oramed’s “oral insulin ORMD-0801 warrants further investigation as a treatment option for patients with inadequately controlled type 2 diabetes, indicate findings from a phase 2b trial presented at the virtual 56th EASD Annual Meeting.”

Read more:  Novel oral insulin shows promise for type 2 diabetes